Astec Lifesciences Ltd

📈 Astec Lifesciences Q4 FY26: Revenue Jumps 34% to ₹161.3 Cr, EBITDA Surges 87%

• Q4 FY26 consolidated total income: ₹161.3 crore, up 34% year-over-year

• Full-year FY26 consolidated total income: ₹453.2 crore, up 17% from FY25

• Enterprise segment revenue up 37% in Q4

• Contract Manufacturing & New Products segment revenue up 30% in Q4

• Domestic sales surged 134% year-over-year in Q4 FY26

• Exports grew 8% in Q4 FY26

• Consolidated EBITDA for Q4 FY26: ₹11.8 crore, an 87% increase

• Full-year FY26 consolidated EBITDA reached breakeven at ₹0.5 crore

• Loss after tax improved to ₹7.7 crore in Q4 FY26 from ₹16.1 crore

• Full-year loss after tax reduced to ₹80.9 crore from ₹134.7 crore